MICB and neoplasm: TGF-β appears to act simultaneously on NK cells and tumor cells via miR-183, with the result to inhibit the NK cells' anti-tumor activity by down-regulating DAP12, in NK cells, and NKG2D ligands (MICA and MICB), in cancer cells.